European Equity pre-Market Summary - 14th September 2026: Global equities fall as AI CEOs voice concerns over the pace of AI development

Stories AstraZeneca (AZN LN) -2.0% - Its Phase 3 Serena 4 trial of Etcamah in combination with palbociclib did not meet the primary endpoint of progression-free survival in patients with breast cancer. GSK (GSK LN) +1.5% - Phase III ARTEMIS-008 trial met its primary overall survival endpoint in relapsed small-cell lung cancer. Euronext (ENX FP) - Co. CEO tells the FT that they are open to a merger with Deutsche Boerse (DB1 GY) or a tie-up between the stock exchange businesses. Pernod Ricard (RI FP) +0.7% - US President Trump announces the removal of US tariffs on Irish whiskey. Broker Moves Stellantis (STLAM IM/STLAP FP) -1.2% - Downgraded to Underweight from Equal Weight at Morgan Stanley Renault (RNO FP) - Upgraded to Equal Weight from Underweight at Morgan Stanley Standard Chartered (STAN LN) - Upgraded to Outperform from Market Perform at Keefe Bruyette Antofagasta (ANTO LN) - Upgraded to Buy from Hold at Berenberg The numbers after the Co. & ticker are the pre-market indication via Tradegate